Marine-Derived Polyketides with Antibiotic Activity

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (15 May 2019) | Viewed by 12420

Special Issue Editor


E-Mail Website
Guest Editor
Institute for Insect Biotechnology, Justus-Liebig-University Giessen, Giessen, 35392, Germany
Interests: specialized metabolites; biosynthesis; drug discovery; anti-infectives Interests: antibiotics; heterologous expression; metabolomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Polyketides are a class of specialized metabolites produced by a wide variety of organisms. Most intriguing is the fact that these compounds show a multitude of biological activities, e.g., antibacterial activities. They are in the focus of research from an ecological, as well as pharmaceutical point of view, since many medicinal drugs are natural polyketides per se, or are based on them. Hence, polyketides possess the potential to become leads for novel medicinal drugs. Especially in the antibiotics field exists a pressing need to identify and evaluate novel structures. The current drugs, contributing to the increased life expectancy of humans, are losing their power due to antimicrobial resistance development and dispersion.

The goal of this Marine Drugs Special Issue is to assemble a collection of scientific articles outlining the diversity, the biosynthesis and the antibiotic potential of marine-derived polyketides.

Scientists from various fields are invited to contribute, to combine interdisciplinary expertise in marine-derived polyketides research, e.g., (micro)biology, analytical chemistry, bioinformatics, pharmacy, and biotechnology.

Prof. Dr. Till F. Schäberle
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Polyketide
  • PKS
  • Mixed PKS/NRPS
  • natural product
  • secondary metabolite
  • specialized metabolite
  • biosynthesis
  • antibiotic
  • antibacterial

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2325 KiB  
Article
Fusarisolins A–E, Polyketides from the Marine-Derived Fungus Fusarium solani H918
by Siwen Niu, Xi-Xiang Tang, Zuowang Fan, Jin-Mei Xia, Chun-Lan Xie and Xian-Wen Yang
Mar. Drugs 2019, 17(2), 125; https://doi.org/10.3390/md17020125 - 20 Feb 2019
Cited by 16 | Viewed by 4357
Abstract
Five new (fusarisolins A–E, 1 to 5) and three known (6 to 8) polyketides were isolated from the marine-derived fungus Fusarium solani H918, along with six known phenolics (9 to 14). Their structures were established by comprehensive spectroscopic [...] Read more.
Five new (fusarisolins A–E, 1 to 5) and three known (6 to 8) polyketides were isolated from the marine-derived fungus Fusarium solani H918, along with six known phenolics (9 to 14). Their structures were established by comprehensive spectroscopic data analyses, methoxyphenylacetic acid (MPA) method, chemical conversion, and by comparison with data reported in the literature. Compounds 1 and 2 are the first two naturally occurring 21 carbons polyketides featuring a rare β- and γ-lactone unit, respectively. All isolates (1 to 14) were evaluated for their inhibitory effects against tea pathogenic fungus Pestalotiopsis theae and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase gene expression. Compound 8 showed potent antifungal activity with an ED50 value of 55 μM, while 1, 8, 13, and 14 significantly inhibited HMG-CoA synthase gene expression. Full article
(This article belongs to the Special Issue Marine-Derived Polyketides with Antibiotic Activity)
Show Figures

Figure 1

16 pages, 1747 KiB  
Article
Cyclopropane-Containing Fatty Acids from the Marine Bacterium Labrenzia sp. 011 with Antimicrobial and GPR84 Activity
by Jamshid Amiri Moghaddam, Antonio Dávila-Céspedes, Stefan Kehraus, Max Crüsemann, Meryem Köse, Christa E. Müller and Gabriele Maria König
Mar. Drugs 2018, 16(10), 369; https://doi.org/10.3390/md16100369 - 8 Oct 2018
Cited by 28 | Viewed by 7287
Abstract
Bacteria of the family Rhodobacteraceae are widespread in marine environments and known to colonize surfaces, such as those of e.g., oysters and shells. The marine bacterium Labrenzia sp. 011 is here investigated and it was found to produce two cyclopropane-containing medium-chain fatty acids [...] Read more.
Bacteria of the family Rhodobacteraceae are widespread in marine environments and known to colonize surfaces, such as those of e.g., oysters and shells. The marine bacterium Labrenzia sp. 011 is here investigated and it was found to produce two cyclopropane-containing medium-chain fatty acids (1, 2), which inhibit the growth of a range of bacteria and fungi, most effectively that of a causative agent of Roseovarius oyster disease (ROD), Pseudoroseovarius crassostreae DSM 16950. Additionally, compound 2 acts as a potent partial, β-arrestin-biased agonist at the medium-chain fatty acid-activated orphan G-protein coupled receptor GPR84, which is highly expressed on immune cells. The genome of Labrenzia sp. 011 was sequenced and bioinformatically compared with those of other Labrenzia spp. This analysis revealed several cyclopropane fatty acid synthases (CFAS) conserved in all Labrenzia strains analyzed and a putative gene cluster encoding for two distinct CFASs is proposed as the biosynthetic origin of 1 and 2. Full article
(This article belongs to the Special Issue Marine-Derived Polyketides with Antibiotic Activity)
Show Figures

Figure 1

Back to TopTop